Showing 241 - 260 results of 395 for search '"Pharmaceutics"', query time: 0.07s Refine Results
  1. 241

    Antibiotic-resistance of H. pylori: results of microbiologic regional investigation by N. N. Dekhnich, E. A. Kostyakova, A. A. Punin, A. V. Alimov, N. V. Ivanchik, R. S. Kozlov

    Published 2011-03-01
    “…Previous intake of antibacterial pharmaceuticals reduced frequency of Н. pylori detection. …”
    Get full text
    Article
  2. 242
  3. 243
  4. 244
  5. 245

    Natural compounds in the management of polycystic ovary syndrome: a comprehensive review of hormonal regulation and therapeutic potential by Jingyi Yuan, Zhenmin Li, Yongjiang Yu, Xiuge Wang, Yunyun Zhao

    Published 2025-02-01
    “…Their multi-target properties offer the potential to achieve outcomes unattainable by single-target pharmaceuticals, particularly in managing heterogeneous conditions. …”
    Get full text
    Article
  6. 246

    Practical Recommendations of Scientific Society for the Study of Human Microbiome and Russian Gastroenterological Association (RGA) for Probiotics in Treatment and Prevention of Ga... by V. T. Ivashkin, I. V. Mayev, D. I. Abdulganieva, S. A. Alekseenko, N. Yu. Ivashkina, N. V. Korochanskaya, S. N. Mammaev, E. A. Poluektova, A. S. Trukhmanov, Yu. P. Uspensky, V. V. Tsukanov, O. S. Shifrin, O. Yu. Zolnikova, K. V. Ivashkin, T. L. Lapina, R. V. Maslennikov, A. I. Ulyanin

    Published 2020-05-01
    “…Probiotics can be registered in the Russian Federation as biologically active food additives (BAFA) or as pharmaceutical products (drugs) in accordance with the microbiological standards and legislative requirements of the Russian Federation. …”
    Get full text
    Article
  7. 247

    A Collaborative Data Network for the Asia Oceania Region Enabled by Emerging Technologies to Foster Innovation in a Secure and Open Environment by Alison Specht, Kim Bryceson, Shoufeng Cao, Margaret O’Brien, S. M. Guru, Pedro Pizzigatti Correa, Michelle Waycott

    Published 2025-01-01
    “…These benefits can be for reporting (state of the environment, achievement of Sustainable Development Goals, conservation objectives), for research (exploration of international phylogenetics, development of new pharmaceuticals), or for economic reasons. Confidence in the value of data is best achieved if the information used to underpin statements and conclusions is open to scrutiny. …”
    Get full text
    Article
  8. 248

    Case report: Bevacizumab-induced cerebrovascular events: a case series report and literature review by Ke Chen, Boyang Jiang, Boyang Jiang, Huiping Yan, Huiping Yan, Liu Yang, Liu Yang, Zheling Chen, Zheling Chen

    Published 2025-02-01
    “…In clinical use, bevacizumab has improved the overall survival (OS) and progression-free survival (PFS) of malignant solid tumors, and the safe use of bevacizumab has gradually become the mainstream direction of clinical, nursing and pharmaceutical research. Bevacizumab is a humanized anti-VEGF drug. …”
    Get full text
    Article
  9. 249

    Advanced Techniques for Glucose Oxidase Immobilization: Evolution, Computational Integration, and Biomedical Applications by G Sreenivasulu, R. Ramakoteswara Rao

    Published 2024-09-01
    “…Glucose oxidase is a crucial enzyme used in industries such as chemicals, pharmaceuticals, food, and biotechnology due to its ability to oxidize glucose into hydrogen peroxide and gluconic acid (C6H12O7). …”
    Get full text
    Article
  10. 250

    Advancements in 3D printing technologies for personalized treatment of osteonecrosis of the femoral head by Tingting Chen, Lincong Luo, Jiaying Li, Jiamin Li, Tao Lin, Mingrui Liu, Hang Sang, Xinyu Hong, Jiahao Pu, Wenhua Huang

    Published 2025-04-01
    “…Three-dimensional (3D) printing technology has shown significant promise in the medical field, particularly in orthopedics, prosthetics, tissue engineering, and pharmaceutical preparations. This review focuses on the innovative application of 3D printing in addressing the challenges of osteonecrosis of the femoral head (ONFH). …”
    Get full text
    Article
  11. 251
  12. 252

    Резолюция Экспертного совета «Диагностика и лечение больных со сладжем в желчном пузыре» by V. T. Ivashkin, Alexey V. Okhlobystin, Dmitry S. Bordin, M. F. Osipenko, E. Ya. Seleznyova, Yu. O. Shulpekova, S. R. Abdulkhakov, O. P. Alexseyeva, I. G. Bakulin, L. G. Vologjhanina, V. B. Grinevich, N. V. Bakulina, T. A. Kolesova, N. V. Korochanskaya, I. V. Putintseva, A. S. Sarsenbayeva, N. S. Yazenok

    Published 2018-08-01
    “…Selective antispasmodic medications (e.g. hymecromone) will be one of the basic pharmaceutical agents in this case, indications to endoscopic treatment should be evaluated, typically - by means of endoscopic ultrasound investigation). …”
    Get full text
    Article
  13. 253

    Digital twin-enhanced three-organ microphysiological system for studying drug pharmacokinetics in pregnant women by Katja Graf, José Martin Murrieta-Coxca, Tobias Vogt, Sophie Besser, Daria Geilen, Tim Kaden, Tim Kaden, Anne-Katrin Bothe, Diana Maria Morales-Prieto, Behnam Amiri, Behnam Amiri, Stephan Schaller, Ligaya Kaufmann, Martin Raasch, Ramy M. Ammar, Ramy M. Ammar, Christian Maass, Christian Maass

    Published 2025-02-01
    “…BackgroundPregnant women represent a vulnerable group in pharmaceutical research due to limited knowledge about drug metabolism and safety of commonly used corticosteroids like prednisone due to ethical and practical constraints. …”
    Get full text
    Article
  14. 254

    Luteolin: exploring its therapeutic potential and molecular mechanisms in pulmonary diseases by Jialian Lv, Xinyue Song, Zixin Luo, Duoqin Huang, Li Xiao, Kang Zou

    Published 2025-02-01
    “…These challenges can be addressed by modifying the chemical structure and enhancing pharmaceutical formulations. We summarized the research advancements in improving the solubility and bioavailability of luteolin, as well as the effects of luteolin on various pulmonary diseases and their related mechanisms, with the aim of providing new ideas for researchers.…”
    Get full text
    Article
  15. 255

    Management of adult patients with alcoholic liver disease: clinical guidelines of the Russian Scientific Liver Society by V. T. Ivashkin, M. V. Mayevskaya, Ch. S. Pavlov, Yu. P. Sivolap, V. D. Lunkov, M. S. Zharkova, R. V. Maslennikov

    Published 2018-08-01
    “…Short therapeutic interventions practice helps to cope with alcoholic issue at any stage, gives the chance to motivate the patient, including the treatment of addiction to alcohol, intake of drugs. Specific pharmaceutical therapy is carried out at alcoholic hepatitis in relation to severity and alcoholic liver cirrhosis. …”
    Get full text
    Article
  16. 256

    Treatment compliance at initial and maintenance therapy at gastroesophageal reflux disease by V. I. Simanenkov, S. V. Tikhonov, N. B. Lischuk

    Published 2018-08-01
    “…Treatment compliance was established according to duration of study participation, along with that patients self-estimated it on 2, 3, 4 and 5 visits by Morisky-Green test and 5-score analog scales of pharmaceutical treatment compliance and lifestyle verification. …”
    Get full text
    Article
  17. 257

    One-pot green synthesis of BSA-capped O-CQDs as an effective fluorescent sensing platform for sensitive and selective detection of promethazine drug by S. Viji, A. Dinesh, K. Radhakrishnan, L. Srimathi Priya, C. Sivasankari, Madhappan Santhamoorthy, Manikandan Ayyar, V. Mohanavel, Mohamed Hashem, Hassan Fouad, G. Ramachandran, S. Santhoshkumar

    Published 2025-02-01
    “…The primary advantages of this technique include simplified sample preparation together with economic advantages which make it a critical instrument for public health monitoring as well as cutting-edge pharmaceutical research. Sustainable O-CQDs demonstrate the potential for creating environmentally friendly biosensors.…”
    Get full text
    Article
  18. 258

    Pervasive systemic disparities: medical-related gaslighting, trauma, and distrust among LGBTQ+ people in the United States by Dustin Z. Nowaskie, Dehandra Blackwood, Frank Garcia

    Published 2025-02-01
    “…Likewise, LGBTQ+ people conveyed significantly less trust (ORs 0.46–0.53) in primary care providers (59.8% vs. 74.1%), medical specialists (56.5% vs. 71.7%), pharmaceutical companies (17% vs. 28%), insurance companies (15.9% vs. 29.3%), and U.S. healthcare systems (17.8% vs. 30.4%).DiscussionMedical-related gaslighting, trauma, and distrust are pervasive systemic disparities among LGBTQ+ people. …”
    Get full text
    Article
  19. 259

    Ideologization and commercialization in pandemic management by Anđelković Maja, Radosavljević Milan, Radosavljević Dragana

    Published 2021-01-01
    “…The crisis of the pandemic and the fight against it is aggravated by migration, environmental, economic and other crises, which means that these are integrated crises to which an integrated or holistic response should be given. Medical and pharmaceutical science and the profession found themselves in a delicate situation, to respond to the challenges of mass infection with the C-19 virus, and both were not prepared to respond to the pandemic, and this disorientation caused "cracks" that led to undermined public confidence in medicine and the subordination of the medical profession to politics. …”
    Get full text
    Article
  20. 260

    Solubility of gemcitabine (an anticancer drug) in supercritical carbon dioxide green solvent: Experimental measurement and thermodynamic modeling by Gholamhossein Sodeifian, Masturah Markom, Jarinah Mohd Ali, Muhammad Zulhaziman Mat Salleh, Reza Derakhsheshpour

    Published 2025-02-01
    “…Abstract In order to develop supercritical fluid (SCF) processes for the micro or nanosizing of solid solute components, such as pharmaceuticals, it is essential to assess their solubility in solvents including supercritical carbon dioxide (SC–CO2). …”
    Get full text
    Article